Author: Singh, Awadhesh Kumar; Gillies, Clare L; Singh, Ritu; Singh, Akriti; Chudasama, Yogini; Coles, Briana; Seidu, Sam; Zaccardi, Francesco; Davies, Melanie J; Khunti, Kamlesh
Title: Prevalence of comorbidities and their association with mortality in patients with COVIDâ€19: A Systematic Review and Metaâ€analysis Cord-id: 9lft1r0b Document date: 2020_6_23
ID: 9lft1r0b
Snippet: AIMS: COVIDâ€19 is a global pandemic that as of the 4th May has registered over 3 585 711 confirmed cases and 248 780 deaths. This review aims to estimate the prevalence of both cardiometabolic and other coâ€morbidities in patients with COVIDâ€19 infection, and to estimate the increased risk of severity and mortality in people with coâ€morbidities. MATERIALS AND METHODS: Medline, Scopus and the World Health Organisation (WHO) website for Global research on COVIDâ€19 were searched from Janua
Document: AIMS: COVIDâ€19 is a global pandemic that as of the 4th May has registered over 3 585 711 confirmed cases and 248 780 deaths. This review aims to estimate the prevalence of both cardiometabolic and other coâ€morbidities in patients with COVIDâ€19 infection, and to estimate the increased risk of severity and mortality in people with coâ€morbidities. MATERIALS AND METHODS: Medline, Scopus and the World Health Organisation (WHO) website for Global research on COVIDâ€19 were searched from January 2019 up to April 23, 2020. Study inclusion was restricted to English language publications, original articles that reported prevalence of coâ€morbidities in individuals with COVIDâ€19 disease, and caseâ€series >10 patients. 18 studies were selected for inclusion. Data were analysed using random effects metaâ€analysis models. RESULTS: Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for coâ€morbidities in patients with COVIDâ€19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension; 11.5% (9.7 to 13.4) for diabetes; and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease, and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all other coâ€morbidities had a significantly increased risk for having severe COVIDâ€19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease, and cancer. CONCLUSIONS: In individuals with COVIDâ€19, the presence of coâ€morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVIDâ€19 and mortality. These findings have important implications for the public health with regards to risk stratification and future planning. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date